CStone Pharmaceuticals ('CStone', HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Type II variation application to the ...

Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...

A consortium of Austrian research groups from the University of Vienna, MedUni Vienna and Technikum Wien, together with ...

Harry H. Yoon, MD, MHS, discusses tislelizumab and platinum-containing chemotherapy in unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 at a level of 1 or ...

Therapy-related B-cell acute lymphoblastic leukemia (B-ALL), a rare form of acute lymphoblastic leukemia (ALL), may develop in patients receiving cytotoxic treatments for a prior malignancy, according ...

The Trial in Progress poster includes an overview and study design of the TACTI-004 Phase III evaluating the Company’s MHC Class II agonist, eftilagimod alfa (efti) in combination with MSD’s (Merck & ...

Stanley Tucci revealed how his treatment, following his throat cancer diagnosis in 2017, is still affecting his body years later.

(HealthDay News) — In a clinical practice guideline issued by the American Society for Radiation Oncology and published online in Practical Radiation Oncology, evidence-based recommendations are ...

A collaborative research team from The University of Hong Kong (HKU) and West China Hospital of Sichuan University has made a breakthrough in understanding the spread of oral squamous cell carcinoma ...

As of December 31, 2024, Pyxis Oncology had cash and cash equivalents, including restricted cash, and short-term investments, of $128.4 million. The Company believes that its current cash, cash ...